|Description||Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.|
|Synonyms||1H-Tetrazole-5-carboxamide, N-(5-(3-(4-acetyl-3-hydroxy-2-propylphenox y)propoxy)-4-chloro-2-methylphenyl)-, monosodium salt;CGP35949;N-(5-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy)-4-chloro-2-methylphenyl)-1H-tetrazole-5-carboxamide monosodium salt;Sodium N-[5-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-4-chloro-2-methylphenyl]-1,2,3-triaza-4-azanidacyclopenta-2,5-diene-5-carboxamide;Sodium 5-((5-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)-4-chloro-2-methylphenyl)carbamoyl)tetrazol-1-ide|
|Solubility||10 mM in DMSO|
|Application||Cgp-35949 represents a new approach to the treatment of asthma.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||597.3°C at 760 mmHg|
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.
CP-195494, a benzothiazol derivative, was once studied as a leukotriene receptor antagonist.
LY-25648 is a leukotriene B4 antagonist.
MK-571 sodium salt hydrate
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
Cinalukast is a selective Leukotriene D4 receptor antagonist originated by Roche and IC 50 value is 6.4 nM. Cinalukast inhibits the actions of Leukotriene D4 at...
CP-199330, a chromen derivative, has been found to be a Leukotriene D4 receptor antagonist that was once studied against asthma by Pfizer.
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of certain natural substances that cau...
HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist. It can inhibit radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC5...
LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal m...
WAY-126299A, a benzothiazoly derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist and was once studied in A...
This active molecular is benzophenone dicarboxylic acid derivative which is a potent BLT1 receptor antagonist. It inhibits the binding of radiolabeled-LTB4 to i...
This active molecular is an potent dual Leukotriene CysLT1 and CysLT2 Receptor antagonist originated by Ono Pharmaceutical. IC50 values is 1.7nM against human C...
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...